Dr. Ostrosky-Zeichner is a professor of medicine and epidemiology, the Vice-Chair of Medicine for Healthcare Quality, and the director of the Laboratory of Mycology Research, at the Division of Infectious Diseases of the McGovern Medical School (a part of UTHealth). He also serves as the medical director for epidemiology and antimicrobial stewardship for Memorial Hermann Texas Medical Center and UT Physicians. He is also currently coordinating the COVID-19 response for UTHealth and its affiliated hospitals and clinics. He is a fellow of the American College of Physicians, the Infectious Diseases Society of America, the Society of Healthcare Epidemiology of America, and the Academy of the European Confederation of Medical Mycology. Dr. Ostrosky-Zeichner is a Senior Editor for the Journal of Antimicrobial Chemotherapy as well as an editorial board member of Antimicrobial Agents and Chemotherapy and Clinical Infectious Diseases. He is President of the Mycoses Study Group Education and Research Consortium and a board member of the International Immunocompromised Host Society. He is also a past chair of the Infectious Diseases Society of America Standards and Practice Guidelines Committee and a consultant to the US FDA and CDC.
Dr. Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program. He has advanced training and experience in medical mycology, healthcare epidemiology, antimicrobial stewardship, general and transplant infectious diseases, and healthcare quality, and he has authored more than 155 peer-reviewed articles while actively pursuing translational research as well as clinical interests on those topics.
An associate professor of clinical medicine at Indiana University School of Medicine, Dr Chadi Hage is ABIM certified in infectious diseases, pulmonary medicine, and critical care medicine, with a strong interest in lung immunology as well as pulmonary infections and fungal diseases. He earned his medical degree at the Lebanese University School of Medicine; completed his internship in internal medicine at the SUNY Health Science Center, Brooklyn, NY; and undertook his Medicine residency and fellowship in infectious disease, pulmonary and critical care medicine at Indiana University. His research and clinical activities are in the fields of fungal infections, lung transplant, ECMO, and transplant critical care.
Dr Hage, board certified, has published extensively on endemic mycoses, particularly histoplasmosis and blastomycosis, fungal infections in immunocompromised patients, as well as outcomes of lung transplants.
Dr. Lunning, Assistant Professor in the Department of Internal Medicine, Division of Oncology & Hematology, has been a faculty member at the University of Nebraska Medical Center since 2013. After pursuing his medical training at Des Moines University College of Osteopathic Medicine, he completed his internal medicine residency at the University of Nebraska Medical Center, including serving a year as Chief Resident. Dr. Lunning then completed his hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. Returning to Omaha, he used his expertise in such hematologic malignancies as non-Hodgkin’s lymphoma and multiple myeloma, working with the Transplant Center at UNMC and presenting results of his research at major association meetings. He has authored many articles on T-cell lymphomas, B-cell lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, as well as on the side effects of chemotherapy. They have appeared in leading publications such as the American Journal of Clinical Oncology; Blood, Leukemia and Lymphoma; and the British Journal of Haematology.
In addition to serving as a member of the graduate student faculty, Dr. Lunning is actively involved in clinical research. He most recently participated in the creation of the National Comprehensive Cancer Network’s practice guidelines on enhanced safety measures for care of oncology patients during the COVID-19 pandemic.
Marisa Haydee Miceli, MD, is an Associate Professor at the University of Michigan specializing in infectious diseases, particularly among transplant recipients. Dr. Miceli graduated from the University of Buenos Aires, Argentina, where she completed training in Internal Medicine, Infectious Diseases and Transplant Infectious Diseases. After migrating to the United States, she spent several years conducting research on the diagnosis of invasive fungal infections in high-risk patients. She completed her residency in internal medicine at Oakwood Hospital & Medical Center, Dearborn, Michigan, fellowships in Infectious Diseases at the University of New Mexico and in Transplant Infectious Diseases at Henry Ford Health System, in Michigan. In 2018 Dr. Miceli was named a fellow of the Infectious Diseases Society of America and is a fellow of the European Confederation of Medical Mycology. She is board certified in both internal medicine and infectious disease. Results of her research into fungal infections, mainly focused on novel diagnostic tools and treatment, have been published in leading journals.
Nathan P. Wiederhold earned his bachelor’s degree in biology and a PharmD in pharmacy at the University of Texas at Austin, after which he joined the faculty of the University of Texas Health Science Center, San Antonio. In 2013, he was named Director of the university's Fungus Testing Laboratory in the Department of Pathology, as well as Adjoint Associate Professor in the College of Pharmacy.
Dr Wiederhold’s research is focused on trends in antifungal resistance, new mechanisms of drug resistance in fungi, and the evaluation of novel agents under development for the treatment of invasive fungal infections, concentrating on the preclinical evaluation of investigational therapeutic modalities and diagnostic technologies for the diagnosis and treatment of fungal infections. This includes both in vitro assessment for activity against a wide range of fungal pathogens, such as multi-drug resistant clinical isolates, and in vivo models of invasive fungal infections. This work, supported through NIH/NIAID contracts and grants from industry, involves close collaboration with other researchers in the Departments of Microbiology and Immunology, Medicine/Infectious Diseases, and Pathology. Dr Wiederhold's laboratory also serves as the central mycology laboratory for several clinical trials and post-marketing studies. The lab’s groups are also interested in evaluating antifungal susceptibility results to determine changes in resistance patterns and in the discovery of novel mechanisms of antifungal resistance. Several new species of fungi have also been discovered by the laboratory in collaboration with other international mycology laboratories, both through morphologic/phenotypic assessment and phylogenetic analysis.